替格鲁巴特治疗肌萎缩侧索硬化患者的安全性与耐受性:一项2A期临床试验
这项多中心、剂量递增、开放标签2A期研究纳入54例肌萎缩侧索硬化(ALS)患者,每2周静脉输注替格鲁巴特共6次,分1、2、4、8 mg/kg四个剂量队列,主要终点为安全性与耐受性。最常见治疗中出现的不良事件为疲乏(25.9%)、跌倒(22.2%)、头痛(20.4%)和肌肉痉挛(11.1%),替格鲁巴特似安全且耐受良好,并呈剂量依赖性降低循环促炎生物标志物。
要点
- 54例ALS患者接受替格鲁巴特6次静脉输注,49/54例(90.7%)完成研究。
- 最常见治疗中出现的不良事件为疲乏25.9%、跌倒22.2%、头痛20.4%、肌肉痉挛11.1%。
- 替格鲁巴特半衰期约24天,抗药抗体滴度低,呈剂量依赖性降低18种循环促炎生物标志物。
核心结论
- 替格鲁巴特在成人ALS患者中似安全且耐受良好,并呈剂量依赖性降低与ALS相关的促炎趋化因子和细胞因子。
- 这些结果需进一步开展有足够把握度和持续时间的临床研究以评估临床结局,作为成人ALS的潜在治疗。
研究设计与样本
- 多中心、剂量递增、开放标签2A期研究,54例确诊ALS的参与者接受每2周静脉输注替格鲁巴特共6次。
- 研究设4个剂量队列:1 mg/kg、2 mg/kg、4 mg/kg和8 mg/kg。
- 主要终点为安全性与耐受性;探索性终点包括药代动力学、抗药抗体反应、采用修订版ALS功能评定量表(ALSFRS-R)的疾病进展变化、CD154靶点结合、促炎生物标志物变化及神经丝轻链(NFL)。
- 共筛查70例受试者,入组54例;49/54例(90.7%)完成研究,接受全部6次替格鲁巴特输注并完成末次随访。
主要发现
- 总体最常见(>10%)的治疗中出现的不良事件为疲乏(25.9%)、跌倒(22.2%)、头痛(20.4%)和肌肉痉挛(11.1%)。
- 替格鲁巴特平均血浆浓度随剂量增加呈比例升高,半衰期约24天。
- 各队列抗药抗体滴度低,替格鲁巴特循环水平与预测值一致。
- 替格鲁巴特呈剂量依赖性靶点结合,并降低循环中18种促炎生物标志物。
局限性
- 原文结论指出这些结果需进一步开展有足够把握度和持续时间的临床研究以评估临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interaction of CD40L and its receptor CD40 on activated T cells and B cells respectively control pro-inflammatory activation in the pathophysiology of autoimmunity and transplant rejection. Previous studies have implicated signaling pathways involving CD40L (interchangeably referred to as CD154), as well as adaptive and innate immune cell activation, in the induction of neuroinflammation in neurodegenerative diseases. This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic lateral sclerosis (ALS). METHODS AND FINDINGS: In this multicenter dose-escalating open-label Phase 2A study, 54 participants with a diagnosis of ALS received 6 infusions of tegoprubart administered intravenously every 2 weeks. The study was comprised of 4 dose cohorts: 1 mg/kg, 2 mg/kg, 4 mg/kg, and 8 mg/kg. The primary endpoint of the study was safety and tolerability. Exploratory endpoints assessed the pharmacokinetics of tegoprubart as well as anti-drug antibody (ADA) responses, changes in disease progression utilizing the Revised ALS Functional Rating Scale (ALSFRS-R), CD154 target engagement, changes in pro-inflammatory biomarkers, and neurofilament light chain (NFL). Seventy subjects were screened, and 54 subjects were enrolled in the study. Forty-nine of 54 subjects completed the study (90.7%) receiving all 6 infusions of tegoprubart and completing their final follow-up visit. The most common treatment emergent adverse events (TEAEs) overall (>10%) were fatigue (25.9%), falls (22.2%), headaches (20.4%), and muscle spasms (11.1%). Mean tegoprubart plasma concentrations increased proportionally with increasing dose with a half-life of approximately 24 days. ADA titers were low and circulating levels of tegoprubart were as predicted for all cohorts. Tegoprubart demonstrated dose dependent target engagement associated and a reduction in 18 pro-inflammatory biomarkers in circulation. CONCLUSIONS: Tegoprubart appeared to be safe and well tolerated in adults with ALS demonstrating dose-dependent reduction in pro-inflammatory chemokines and cytokines associated with ALS. These results warrant further clinical studies with sufficient power and duration to assess clinical outcomes as a potential treatment for adults with ALS. TRIAL REGISTRATION: Clintrials.gov ID:NCT04322149.
引用
- Perrin S, Ladha S, Maragakis N, et al. Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial. PLoS Med. 2024. PMID: 39480764. doi:10.1371/journal.pmed.1004469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。